Intelligent Bio Solutions (INBS) just unveiled an announcement.
Intelligent Bio Solutions Inc. has announced the initiation of subject screening for its pivotal pharmacokinetic study, which is a significant step in the FDA 510(k) clearance process for their product. This milestone underscores the company’s progress in meeting regulatory requirements and advancing towards market readiness.
For an in-depth examination of INBS stock, go to TipRanks’ Stock Analysis page.
